Precision BioSciences, Inc. (DTIL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Precision BioSciences, Inc. (DTIL)
Go deeper and ask any question about DTIL
Company Performance
Current Price
as of Sep 13, 2024$10.30
P/E Ratio
N/A
Market Cap
$74.51M
Description
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Metrics
Overview
- HQDurham, NC
- SectorHealth Technology
- IndustryBiotechnology
- TickerDTIL
- Price$10.3-1.81%
Trading Information
- Market Cap$74.51M
- Float91.58%
- Average Daily Volume (1m)42,940
- Average Daily Volume (3m)36,764
- EPS-$1.97
Company
- Revenue$87.64M
- Rev Growth (1yr)152.15%
- Net Income$32.75M
- Gross Margin97.23%
- EBITDA Margin51.16%
- EBITDA$25.53M
- EV-$24.54M
- EV/Revenue-0.28
- P/EN/A
- P/S0.82